MedDataX Logo

Intravenous Infusion of Lidocaine in ERCP

NCT03996577 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-09-23

No results posted yet for this study

Summary

Intravenous infusion of lidocaine significantly reduces propofol dose for ERCP and improve patients' recovery after ERCP.

Conditions

  • Sedation

Interventions

DRUG

Lidocaine

the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h

DRUG

placebo

the control group will be given the same volume of saline.

Sponsors & Collaborators

  • Shandong University

    lead OTHER

Principal Investigators

  • yanqing li · Qilu Hospital of Shandong University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-15
Primary Completion
2019-10-15
Completion
2019-11-15

Countries

  • China

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03996577 on ClinicalTrials.gov